Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 15/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.61 |
| ▸ | CSNK2B | P67870 | 5/20 | 0.61 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759472 | 0.86 | PIM1 (0.66) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1760711 | 0.80 | CSNK2A2 (0.82) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1815017 | 0.80 | PIM1 (1.00) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10325090 | 0.78 | PIM1 (0.66) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1815696 | 0.78 | PIM1 (0.65) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL1819537 | 0.73 | CSNK2A2 (0.83) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10322908 | 0.71 | PIM1 (1.00) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10322725 | 0.70 | PIM1 (0.81) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10323990 | 0.68 | PIM1 (0.67) | PIM1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10324309 | 0.68 | PIM1 (0.83) | PIM1CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011058139-A1 | A COMPOUND, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, A METHOD FOR MODULATING OR REGULATING SERINE/THREONINE KINASES AND A SERINE/THREONINE KINASES MODULATING AGENT | SELVITA SP. Z O. O. (PL) | 2011-05-19 | — | — | WO | disclosed |